DDInter992 DDInter636
A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014. As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold). Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart failure regardless of ejection fraction.[L40783,L13916]
Isoxsuprine {u} (Compound) resembles {v} (Compound) Pseudoephedrine
Pseudoephedrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Isoxsuprine {u} (Compound) resembles {v} (Compound) Labetalol
Labetalol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Isoxsuprine {u} (Compound) resembles {v} (Compound) Pseudoephedrine
Pseudoephedrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Timolol
Timolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Isoxsuprine {u} (Compound) resembles {v} (Compound) Phenylpropanolamine
Phenylpropanolamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Vilanterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Isoxsuprine {u} (Compound) resembles {v} (Compound) Labetalol
Labetalol {u} may lead to a major life threatening interaction when taken with {v} Vilanterol
Vilanterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Isoxsuprine {u} (Compound) resembles {v} (Compound) Monobenzone
Monobenzone {u} (Compound) resembles {v} (Compound) Benzphetamine
Benzphetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Isoxsuprine {u} (Compound) resembles {v} (Compound) Ephedrine
Ephedrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Timolol
Timolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Isoxsuprine {u} (Compound) resembles {v} (Compound) Phenylpropanolamine
Phenylpropanolamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methyldopa
Methyldopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Isoxsuprine {u} (Compound) resembles {v} (Compound) Bromodiphenhydramine
Bromodiphenhydramine {u} (Compound) resembles {v} (Compound) Promazine
Promazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Isoxsuprine {u} (Compound) resembles {v} (Compound) Ephedrine
Ephedrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Vilanterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Isoxsuprine (Compound) resembles Pseudoephedrine (Compound) and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Isoxsuprine (Compound) resembles Labetalol (Compound) and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Isoxsuprine (Compound) resembles Pseudoephedrine (Compound) and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Isoxsuprine (Compound) resembles Phenylpropanolamine (Compound) and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Isoxsuprine (Compound) resembles Labetalol (Compound) and Labetalol may lead to a major life threatening interaction when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Isoxsuprine (Compound) resembles Monobenzone (Compound) and Monobenzone (Compound) resembles Benzphetamine (Compound) and Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Isoxsuprine (Compound) resembles Ephedrine (Compound) and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Isoxsuprine (Compound) resembles Phenylpropanolamine (Compound) and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Isoxsuprine (Compound) resembles Bromodiphenhydramine (Compound) and Bromodiphenhydramine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Isoxsuprine (Compound) resembles Ephedrine (Compound) and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin